Similarly to the BCR-ABL-transduced CB cells, primary BC CML cells also showed marked proliferative disadvantage upon downregulation of RAC2, with RAC1 depletion having little effect (Fig 1G). The gene discussed is RAC2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.